To gain tauopathies candidate, BMS pays $175mm up front for iPierian
Bristol-Myers Squibb Co. paid $175mm up front for private neurodegenerative disease company iPierian Inc., which is also entitled to $550mm in development and regulatory earn-outs, plus net sales royalties.
- Large Molecule
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.